<DOC>
	<DOCNO>NCT01105533</DOCNO>
	<brief_summary>This study test new cancer medication determine medication block blood supply tumor decrease growth tumor . This study also define safety profile define safest dose new medication people cancer .</brief_summary>
	<brief_title>A Dose Finding Study Of A New Medication , PF-00337210 That Will Possibly Decrease Blood Supply To Tumors</brief_title>
	<detailed_description />
	<criteria>Histologically cytologically confirm advanced solid tumor unresponsive currently available therapy standard therapy . At least 1 measurable disease site define Response Evaluation Criterion Solid Tumors [ RECIST ] . Adequate bone marrow , liver function renal function define protocol . Blood pressure Requirements During dose escalation evidence preexist hypertension antihypertensive medication baseline . During dose expansion patient 's whose hypertension control antihypertensive therapy . Chemotherapy , radiotherapy investigational therapy within 4 week study entry Current use anticipate need drug know CYP34 inhibitor inducer . Patients carcinomatous meningitis untreated brain metastasis . Any acute cardiovascular incident within past 12 month . Patients active gastrointestinal bleeding significant gastrointestinal abnormality define protocol Patients evidence follow 5 year : malignancy metastatic disease skin cancer ( except melanoma ) , situ cervical cancer breast cancer T1C prostate cancer .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>VGEF inhibitor</keyword>
	<keyword>Anti angiogenesis</keyword>
	<keyword>Advanced Solid Tumors</keyword>
</DOC>